

CROI 2025 Report Back: Treatment Updates

Jehan Budak, MD Assistant Professor Division of Infectious Diseases University of Washington

Last Updated: 10 April 2025





No conflicts of interest or relationships to disclose.



Disclaimer

Funding for this presentation was made possible by 1 TR7HA53202-01-00 from the Human Resources and Services Administration HIV/AIDS Bureau. The views expressed do not necessarily reflect the official policies of the Department of Health and Human Services nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. *Any trade/brand names for products mentioned during this presentation are for training and identification purposes only.*



Outline

• LA CAB-RPV

- CARES 96 Week Data
- More Observational Data
- Outcomes in PWH with Viremia
- CAB-RPV in Pregnancy
- Stopping CAB-RPV

• DOR-ISL





LA CAB-RPV Updates



CARES: Study Design

- Phase 3b, Randomized, Open-Label, Active-Controlled, Non-Inferiority Study
 - \geq 18 years of age
 - On stable oral TDF + XTC + DTG or NVP or EFV
 - HIV-1 RNA < 50 copies/mL at ≥4-12 prior to and at screening
 - No history of renal failure
 - No HBV infection
- HIV-1 RNA checked every 24 weeks
- Due to a public health approach to enrollment, resistance analysis performed during therapy and proviral DNA was performed for archived resistance on stored PBMCs
- Study sites in Uganda, Kenya, and Tanzania

Oral ART Standard of Care (SOC) n = 256

CAB-RPV q 8 weeks +/- 4-week oral lead-in n = 256



CARES: Key Baseline Characteristics

Characteristic	CAB + RPV LA (n=255)	Oral ART (SOC) (n=257)	Overall (n=512)
BMI ≥ 30 kg/m², n (%)	57 (22)	52 (20)	108 (21)
Time on 1 st line ART regimen, median (IQR), years	8 (4-13)	7 (4-13)	8 (4-13)
Prior exposure to NNRTI, n (%)	189 (74)	191 (74)	380 (74)
INSTI regimen at screening	231 (91)	240 (93)	471 (92)
Archived DNA analysis*+			
Viral subtype A1, n/n (%)	116/218 (53)	120/215 (56)	236/433 (55)
RPV resistance mutations, n/n (%)	14/208 (7)	16/193 (8)	30/401 (7)
CAB resistance mutations, n/n (%)	8/99 (8)	12/103 (12)	20/202 (10)

*Retrospective, batched sequencing performed on archived viral DNA extracted from PBMCs stored at baseline


+Viral subtype, RAMs, and drug susceptibility determined using the Los Alamos National Laboratory Panel, IAS-USA 2022 mutations list, and Stanford algorithm respectively. APOBEC-related mutations were excluded.



Kityo CM et al, CROI 2025 #202.

CARES: Week 96 Results

- LA CAB-RPV demonstrated noninferior virologic efficacy as compared to oral standard of care ART
- 77% had an injection site reaction (ISR)
- Over 99% on LA CAB-RPV preferred injectable to daily oral therapy
- 81% of participants received injections within the 7-day target window
- 4 cases of virologic failure (1.6%)





CARES: Virologic Failures at Week 96

confirmed virological f	failure (VL ≥ 200 copies/n	CAB + RPV LA nl x 2) 4 (1.6%)	Oral ART 0	Difference (95% Cl) 1.6% (0.4 to 4.2)
	Participant 1	Participant 2	Participant 3	Participant 4
At confirmed virological	failure			
Week of failure	48	48	72	72
Viral load, copies/ml	8,608 and 1612	44,984, no repeat	798 and 563	259 and 16,161
RPV mutations (level) ††	V108I, E138K (intermediate)	K103N/S, V106V/A, E138A, M230M/L (high)	Test Failed	E138A (low)
CAB mutations (level CAB, DTG) ++*	E92E/V, N155H, L74M (intermed., potential low)	G118R (high, high)	Test Failed	Q148R (M50I) (high, low)
At baseline				
RPV mutations (level) †	Nil	K103N/S, E138A (low)	E138K (low)	Nil
CAB mutations (level) +	L74M (low)	Nil	Test Failed	Nil
Viral subtype +	A1	D	A1	С
BMI, kg/m ²	25.9	22.0	22.2	19.9



Kityo CM et al, CROI 2025 #202.

CARES: Conclusions

 At Week 96, LA CAB-RPV q 8 weeks administered in public health settings in sub-Saharan Africa was non-inferior in virologic efficacy to oral standard of care, had a good safety profile, and was well tolerated

 4 cases of VF occurred in the LA CAB-RPV arm, with emergence of INSTI-R and NNRTI-R

 This remains an important contribution not only regarding broad implementation in sub-Saharan Africa using a public health approach, but also in individuals with high exposure to NNRTIs and pre-treatment resistance, and different subtypes of HIV-1



Key Highlights from CAB-RPV Observational Data

- 1. Viral Suppression (VS) in the OPERA Cohort
- 2. VS in Women in the OPERA Cohort
- 3. VS in the TRIO Cohort



Key Highlights from CAB-RPV Observational Data

- VS in OPERA Cohort¹
 - Of 2,618 PWH who started CAB-RPV, 83% were on CAB-RPV at end of study period
 - With a median follow up of 11 months, 95% had VS
 - After a median of 7 months, 21 (1%) had confirmed virologic failure (CVF)
- VS in Women in the OPERA Cohort²
 - Of 532 women who started CAB-RPV, 78% were on CAB-RPV at end of study period
 - With a median follow up of 12 months, 94% had VS, and 5 (≤ 1.3%) had CVF
- VS in the TRIO Cohort³
 - Of 1198 virally suppressed PWH, 79% were on CAB-RPV at the end of the study period
 - With a median follow up of 12 months, 95% had VS, and 15 (1.6%) had CVF
 - 5/15 CVF had genotypic data

- 3 had RPV-R (Y181C+G190S; K101E; Y181C), 1 of whom had CAB-R (S147G+N155H)

1-Sension M et al, CROI 2025 #674. 2-Altamirano JA et al, CROI 2025 #676. 3-Sax PE et al, CROI 2025 #675.

Outcomes Among PWH Initiating CAB-RPV with Viremia

- 1. Ward 86: 370 PWH on CAB-RPV 129 (35%) initiated with HIV RNA > 30 copies/mL¹
 - 97.9% achieved and maintained VS at 48 weeks
 - No statistically significant difference in VS between those VS or with viremia at baseline
- **2. Ponce Clinic:** 361 PWH on CAB-RPV 81 (22%) initiated with HIV RNA > 50 copies/mL²
 - 69% on CAB-RPV only, 28% on CAB and/or RPV + LEN, 2% on CAB/RPV + LEN + IBA
 - 92% (72/79) achieved VS
 - Of the 6 who did not achieve VS:
 - 2 had VF with NNRTI and INSTI resistance associated mutations (RAMs)
 - 2 had persistent low-level viremia
 - 2 had HIV RNA levels 1000-3000 without RAMs



1-Gistand NL et al, CROI 2025 #689. 2-Colasanti JA et al, CROI 2025 #690.

CAB-RPV in Pregnancy

 Little is known about the safety, efficacy, and outcomes of CAB-RPV use in pregnancy

- Multicenter retrospective chart review of pregnant women prescribed LA CAB-RPV
 - 23 women received LA CAB-RPV during pregnancy (11 q4w, 12 q8w)
 - 73% initiated prior to pregnancy, 27% switched to it during pregnancy
 - Viral suppression at delivery
 - Among those who stayed on CAB-RPV, 20/21 had HIV RNA < 200 copies/mL
 - One person had a HIV RNA > 1000 copies/mL
 - Neonatal outcomes
 - 81% of newborns received zidovudine only post-delivery
 - No cases of vertical transmission

Short WR et al, CROI 2025 #1015



Why do people stop CAB-RPV?

- Ward 86 retrospective chart review of 437 PWH starting CAB-RPV
 - Median time on treatment 553 days
 - 69 (16%) discontinued treatment
 - 30% were on q8w dosing
 - Among those who started with VS, most common reason for discontinuation was pain
 - Among those who started viremic, lateness [of injections] and virologic failure drove discontinuation

Overall	HIV VL <50	HIV VL ≥50
(n - 60)		
(11-09)	copies/mL (n=47)	copies/mL (n=22)
14	10	4
11	9	2
14	11	3
5	5	-
2	2	-
1	1	-
2	2	-
8	2	6
1	1	-
3	3	-
7	1	6
1	-	1
	11 14 5 2 1 2 8 1 3	14 10 11 9 14 11 5 5 2 2 1 1 2 2 1 1 3 3

*Other side effect/concern (not mutually exclusive): flu-like symptoms (7), weight gain (2), fatigue (2), patient concern about efficacy (3), mistrust/misunderstanding (2), muscle spasms (1) injection site abscesses (1), bloating (1), sleep/appetite concern (1), patient desire for control of HIV treatment (1), feeling "stuck in a jar" (1), wanted to "take a break" (1), feeling like "too much medicine" in body (1), discomfort with subcutaneous lenacapavir injections given for intensification of treatment regimen

MWAETC

Why do people stop CAB-RPV?

- UCSD Owen Clinic retrospective chart review of 465 PWH starting CAB-RPV
 - Median time on treatment 164d
 - 92 (19.7%) discontinued treatment
 - >90% of those who restarted oral ART had VS
 - 1 person developed NNRTI-R during PK tail
 - Baseline HIV RNA 44 copies/mL, no RAMs
 - After 2 injections, lost to follow up
 - Re-established care after 9 months
 - HIV RNA: 36,300 copies/mL
 - Genotype: Y181C
 - Concurrent proviral DNA: A98G, E138Q, V179I, Y181C, M230L

Reason for stopping LAI CAB/RPV	n (%)
Injection site reaction (ISR)	26 (28.3)
Side effect other than ISR	11 (12.0)
Difficulty coming in for injections	8 (8.7)
Lost to follow-up but returned to care*	7 (7.6)
Lost to follow-up and did not return	5 (5.4)
Insurance challenges	10 (10.9)
Virologic Failure	6 (6.5)
Concern about HBV reactivation	2 (2.2)
Deceased	5 (5.4)
Pregnancy	2 (2.2)
Other/Not documented	10 (10.9)



Faggiano T et al, CROI 2025 # 685.



DOR-ISL





- Islatravir (ISL) is a nucleoside reverse transcriptase translocation inhibitor (NRTTI)
 - Prior studies with higher doses ISL had declines in CD4 T-cell and total lymphocyte count (TLC)
 - Studies being repeated with lower dose ISL (0.25mg) with DOR
- Among 513 VS PWH on B/F/TAF randomized 2:1 to DOR/ISL QD (342) vs. continued B/F/TAF (171), VS was high and DOR/ISL was non-inferior at 48w¹
 - 2 PWH in ISL-DOR had HIV RNA > 200 copies/mL but no treatment emergent resistance
 - 2 PWH on ISL-DOR and 1 on B/F/TAF discontinued due to decrease in CD4 T-cell or TLC
- Among 551 VS PWH on baseline ART (bART) randomized 2:1 to DOR/ISL QD (366) vs. continued bART (185), VS was high and DOR/ISL was non-inferior at 48w²
 - 5 PWH in ISL-DOR arm had VF but no treatment emergent resistance

1-Colson A et al, CROI 2025 #204A. 2-Orkin C et al, CROI 2025 #204B.



Conclusions

- 1. Week 96 CARES data demonstrated that LA CAB-RPV was non-inferior to oral SOC in sub-Saharan Africa.
- 2. In observational cohorts of individuals on CAB-RPV, VS remains high, including in people starting viremic.
- 3. LA CAB-RPV may be a viable option in pregnancy, but more studies are needed.
- 4. In clinics with large numbers on CAB-RPV, approximately 15-20% of PWH have discontinued injections, mostly due to pain/injection site reactions.
- 5. DOR-ISL appears efficacious and safe at a dose of 100mg/0.25mg in phase 3 trials.



This Mountain West AIDS Education and Training (MWAETC) program is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of award 1 TR7HA53202-01-00 totaling \$2,982,063 with 0% financed with non-governmental sources.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.

